Effects of Empagliflozin on Cardiovascular and Renal Outcomes in Heart Failure with Reduced Ejection Fraction According to Age: a Secondary Analysis of EMPEROR-Reduced
Eur J Heart Fail. 2022; online ahead of print DOI: 10.1002/ejhf.2707
Results from EMPEROR-Reduced demonstrated that empagliflozin improved CV and renal outcomes in patients with HFrEF, but its efficacy and safety across patient's age is not well established.
A secondary analysis of EMPEROR-Reduced assessed the effects of empagliflozin vs placebo, on top of standard HF therapy, in symptomatic HFrEF patients by age subgroups (<65, 65–74, ≥75 years). Of 3,730 patients, 38% were <65 years, 35% were 65–74 years and 27% were ≥75 years. Compared with placebo, empagliflozin reduced the primary endpoint of CV death or HF hospitalisation consistently across the three age groups. The effects of empagliflozin were also consistent across age groups for key secondary endpoints of first and recurrent HF hospitalisation, the rate of decline in eGFR and the renal composite.
Adverse events, serious AEs and AEs leading to drug discontinuation increased with age in both treatment arms, but empagliflozin did not increase their incidence over placebo within each age group.